Stefan Salcher
Overview
Explore the profile of Stefan Salcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daum S, Decristoforo L, Mousa M, Salcher S, Plattner C, Hosseinkhani B, et al.
Mol Cancer
. 2025 Jan;
24(1):21.
PMID: 39819502
The dynamic interactions between tumor endothelial cells (TECs) and the immune microenvironment play a critical role in the progression of non-small cell lung cancer (NSCLC). In general, endothelial cells exhibit...
2.
Schoepf A, Gebhart M, Federspiel M, Heidegger I, Puhr M, Hotze M, et al.
J Med Chem
. 2024 Dec;
68(1):287-306.
PMID: 39693499
The present structure-activity relationship study investigates the development of novel chemosensitizers targeting therapy-resistant cancer stem cells (CSCs). We used 4'-((2-propyl-1-benzo[]imidazole-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid, derived from the angiotensin II type 1 receptor blocker...
3.
Scheiber A, Trebo M, Pittl A, Heidegger I, Hautz T, Oberhuber R, et al.
STAR Protoc
. 2024 Dec;
5(4):103475.
PMID: 39661509
The successful recovery of immune cells, particularly those with low mRNA content, by single-cell RNA sequencing (scRNA-seq) remains a significant challenge. Tissue dissociation and selection of the appropriate scRNA-seq technology...
4.
Gebhart M, Alilou M, Gust R, Salcher S
Eur J Med Chem
. 2024 Dec;
283:117106.
PMID: 39637828
Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of...
5.
Hautz T, Hackl H, Gottschling H, Gronauer R, Hofmann J, Salcher S, et al.
EBioMedicine
. 2024 Sep;
108:105330.
PMID: 39299005
Background: A better understanding of the molecular events during liver normothermic machine perfusion (NMP) is warranted to develop a data-based approach for the identification of biomarkers representative of graft quality...
6.
Heidegger I, Frantzi M, Salcher S, Tymoszuk P, Martowicz A, Gomez-Gomez E, et al.
Eur Urol Oncol
. 2024 Jun;
PMID: 38851995
Background And Objective: While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic,...
7.
Salcher S, Heidegger I, Untergasser G, Fotakis G, Scheiber A, Martowicz A, et al.
Heliyon
. 2024 May;
10(7):e28358.
PMID: 38689972
The development of single-cell omics tools has enabled scientists to study the tumor microenvironment (TME) in unprecedented detail. However, each of the different techniques may have its unique strengths and...
8.
Wolf D, Salcher S, Pircher A
J Clin Invest
. 2024 Mar;
134(5).
PMID: 38426495
Colorectal cancer (CRC) is among the most common cancer types and the second deadliest malignancy for both sexes. Metastatic disease poses substantial therapeutic challenges, and peritoneal spread, in particular, reduces...
9.
Horvath L, Puschmann C, Scheiber A, Martowicz A, Sturm G, Trajanoski Z, et al.
Trends Cancer
. 2024 Feb;
10(5):457-474.
PMID: 38360439
Neutrophils represent the most abundant myeloid cell subtype in the non-small-cell lung cancer (NSCLC) tumor microenvironment (TME). By anti- or protumor polarization, they impact multiple aspects of tumor biology and...
10.
Nagl L, Horvath L, Salcher S, Wolf D, Pircher A
Transl Lung Cancer Res
. 2023 Oct;
12(9):1959-1965.
PMID: 37854164
No abstract available.